307 related articles for article (PubMed ID: 26876462)
1. PLK-1 Silencing in Bladder Cancer by siRNA Delivered With Exosomes.
Greco KA; Franzen CA; Foreman KE; Flanigan RC; Kuo PC; Gupta GN
Urology; 2016 May; 91():241.e1-7. PubMed ID: 26876462
[TBL] [Abstract][Full Text] [Related]
2. Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer.
Nogawa M; Yuasa T; Kimura S; Tanaka M; Kuroda J; Sato K; Yokota A; Segawa H; Toda Y; Kageyama S; Yoshiki T; Okada Y; Maekawa T
J Clin Invest; 2005 Apr; 115(4):978-85. PubMed ID: 15761500
[TBL] [Abstract][Full Text] [Related]
3. Silencing of polo-like kinase (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells.
Bu Y; Yang Z; Li Q; Song F
Oncology; 2008; 74(3-4):198-206. PubMed ID: 18714168
[TBL] [Abstract][Full Text] [Related]
4. Impact of PLK-1 silencing on endothelial cells and cancer cells of diverse histological origin.
Gomes CP; Gomes-da-Silva LC; Ramalho JS; de Lima MC; Simões S; Moreira JN
Curr Gene Ther; 2013 Jun; 13(3):189-201. PubMed ID: 23531193
[TBL] [Abstract][Full Text] [Related]
5. siRNA targeting PLK-1 induces apoptosis of synoviocytes in rheumatoid arthritis.
Wada M; Kawahito Y; Kimura S; Kohno M; Ishino H; Kimura M; Omoto A; Yamamoto A; Hamaguchi M; Tsubouchi Y; Tokunaga D; Hojo T; Ashihara E; Maekawa T; Yoshikawa T
Biochem Biophys Res Commun; 2007 Jun; 357(2):353-9. PubMed ID: 17434144
[TBL] [Abstract][Full Text] [Related]
6. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer.
Reagan-Shaw S; Ahmad N
FASEB J; 2005 Apr; 19(6):611-3. PubMed ID: 15661849
[TBL] [Abstract][Full Text] [Related]
7. A combination of a DNA-chimera siRNA against PLK-1 and zoledronic acid suppresses the growth of malignant mesothelioma cells in vitro.
Kawata E; Ashihara E; Nakagawa Y; Kiuchi T; Ogura M; Yao H; Sakai K; Tanaka R; Nagao R; Yokota A; Takeuchi M; Kimura S; Hirai H; Maekawa T
Cancer Lett; 2010 Aug; 294(2):245-53. PubMed ID: 20206440
[TBL] [Abstract][Full Text] [Related]
8. [PLK1 Expression in Mantle Cell Lymphoma and Its Clinical Significance].
Shen LY; Lin CM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Jun; 27(3):833-838. PubMed ID: 31204940
[TBL] [Abstract][Full Text] [Related]
9. Occurrence of Aurora A positive multipolar mitoses in distinct molecular classes of colorectal carcinomas and effect of Aurora A inhibition.
Herz C; Schlürmann F; Batarello D; Fichter CD; Schöpflin A; Münch C; Hauschke D; Werner M; Lassmann S
Mol Carcinog; 2012 Sep; 51(9):696-710. PubMed ID: 21739483
[TBL] [Abstract][Full Text] [Related]
10. RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer.
Seth S; Matsui Y; Fosnaugh K; Liu Y; Vaish N; Adami R; Harvie P; Johns R; Severson G; Brown T; Takagi A; Bell S; Chen Y; Chen F; Zhu T; Fam R; Maciagiewicz I; Kwang E; McCutcheon M; Farber K; Charmley P; Houston ME; So A; Templin MV; Polisky B
Mol Ther; 2011 May; 19(5):928-35. PubMed ID: 21364537
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer.
McCarroll JA; Dwarte T; Baigude H; Dang J; Yang L; Erlich RB; Kimpton K; Teo J; Sagnella SM; Akerfeldt MC; Liu J; Phillips PA; Rana TM; Kavallaris M
Oncotarget; 2015 May; 6(14):12020-34. PubMed ID: 25557168
[TBL] [Abstract][Full Text] [Related]
12. [Enhancive effect of PLK1 gene silencing on sensitivity of K562/A02 cells to adriamycin].
Liu L; Zhang M; Zou P; Tian L; Liu F
Ai Zheng; 2006 Apr; 25(4):404-8. PubMed ID: 16613670
[TBL] [Abstract][Full Text] [Related]
13. Polo-like kinase 1 is a potential therapeutic target in human melanoma.
Jalili A; Moser A; Pashenkov M; Wagner C; Pathria G; Borgdorff V; Gschaider M; Stingl G; Ramaswamy S; Wagner SN
J Invest Dermatol; 2011 Sep; 131(9):1886-95. PubMed ID: 21654832
[TBL] [Abstract][Full Text] [Related]
14. [Influence of silencing Polo-like kinase 1 on migration and invasion of colorectal cancer cells].
Han DP; Cui JT; Lu AG; Chen XH; Feng B; Zong YP; Qu S; Cao QF; Zheng MH
Zhonghua Wei Chang Wai Ke Za Zhi; 2011 Jan; 14(1):61-4. PubMed ID: 21271384
[TBL] [Abstract][Full Text] [Related]
15. [Knockdown of PLK1 mRNA by special siRNA].
Chen GX; Dong QH; Zhang JW; Fu FF; Xu ZF; Liang QY; Zheng S; Ding JY
Yi Chuan; 2006 Jan; 28(1):21-5. PubMed ID: 16469711
[TBL] [Abstract][Full Text] [Related]
16. Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer.
Kawata E; Ashihara E; Kimura S; Takenaka K; Sato K; Tanaka R; Yokota A; Kamitsuji Y; Takeuchi M; Kuroda J; Tanaka F; Yoshikawa T; Maekawa T
Mol Cancer Ther; 2008 Sep; 7(9):2904-12. PubMed ID: 18790771
[TBL] [Abstract][Full Text] [Related]
17. [Effect of PLK1 gene silence on cell cycle, proliferation and drug resistance in K562/A02 cells].
Liu L; Zhang M; Zou P; Tian L; Liu F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Apr; 14(2):241-6. PubMed ID: 16638189
[TBL] [Abstract][Full Text] [Related]
18. Impact of anti-PLK1 siRNA-containing F3-targeted liposomes on the viability of both cancer and endothelial cells.
Gomes-da-Silva LC; Ramalho JS; Pedroso de Lima MC; Simões S; Moreira JN
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):356-64. PubMed ID: 23659854
[TBL] [Abstract][Full Text] [Related]
19. The expression of PLK-1 in cervical carcinoma: a possible target for enhancing chemosensitivity.
Zhang Y; Liu Y; Yang YX; Xia JH; Zhang HX; Li HB; Yu CZ
J Exp Clin Cancer Res; 2009 Sep; 28(1):130. PubMed ID: 19775446
[TBL] [Abstract][Full Text] [Related]
20. Polo-like kinase and survivin are esophageal tumor-specific promoters.
Sato F; Abraham JM; Yin J; Kan T; Ito T; Mori Y; Hamilton JP; Jin Z; Cheng Y; Paun B; Berki AT; Wang S; Shimada Y; Meltzer SJ
Biochem Biophys Res Commun; 2006 Apr; 342(2):465-71. PubMed ID: 16487489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
